A detailed history of Deka Bank Deutsche Girozentrale transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 3,782,490 shares of BMY stock, worth $213 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares
3,782,490
Previous 4,236,531 10.72%
Holding current value
$213 Million
Previous $177 Million 9.49%
% of portfolio
0.36%
Previous 0.32%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$39.66 - $51.75 $18 Million - $23.5 Million
-454,041 Reduced 10.72%
3,782,490 $194 Million
Q2 2024

Aug 08, 2024

BUY
$40.25 - $52.99 $13.8 Million - $18.1 Million
342,143 Added 8.79%
4,236,531 $177 Million
Q1 2024

Apr 24, 2024

SELL
$47.98 - $54.4 $2.67 Million - $3.03 Million
-55,692 Reduced 1.41%
3,894,388 $209 Million
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $2.74 Million - $3.27 Million
-56,542 Reduced 1.41%
3,950,080 $203 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $3 Million - $3.35 Million
-51,769 Reduced 1.28%
4,006,622 $233 Million
Q2 2023

Jul 25, 2023

BUY
$63.71 - $70.74 $2.6 Million - $2.89 Million
40,886 Added 1.02%
4,058,391 $261 Million
Q1 2023

Apr 24, 2023

BUY
$65.71 - $74.53 $19 Million - $21.6 Million
289,615 Added 7.77%
4,017,505 $273 Million
Q4 2022

Feb 01, 2023

BUY
$68.48 - $81.09 $10.7 Million - $12.6 Million
155,558 Added 4.35%
3,727,890 $267 Million
Q3 2022

Nov 02, 2022

BUY
$0.13 - $76.84 $18,599 - $11 Million
143,072 Added 4.17%
3,572,332 $257 Million
Q2 2022

Aug 03, 2022

SELL
$72.62 - $79.98 $380,601 - $419,175
-5,241 Reduced 0.15%
3,429,260 $264 Million
Q1 2022

Apr 28, 2022

BUY
$61.48 - $73.72 $23.1 Million - $27.7 Million
375,680 Added 12.28%
3,434,501 $253 Million
Q4 2021

Feb 02, 2022

SELL
$53.63 - $62.52 $9.7 Million - $11.3 Million
-180,921 Reduced 5.58%
3,058,821 $191 Million
Q3 2021

Oct 22, 2021

BUY
$59.17 - $69.31 $5.57 Million - $6.52 Million
94,087 Added 2.99%
3,239,742 $196 Million
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $32.9 Million - $35.9 Million
531,821 Added 20.35%
3,145,655 $208 Million
Q1 2021

Apr 28, 2021

BUY
$59.34 - $66.74 $5.2 Million - $5.85 Million
87,710 Added 3.47%
2,613,834 $165 Million
Q4 2020

Mar 12, 2021

BUY
$57.74 - $65.43 $1.55 Million - $1.76 Million
26,867 Added 1.07%
2,526,124 $156 Million
Q3 2020

Oct 29, 2020

BUY
$57.43 - $63.64 $39 Million - $43.2 Million
678,409 Added 37.26%
2,499,257 $148 Million
Q2 2020

Aug 04, 2020

BUY
$54.82 - $64.09 $1.74 Million - $2.04 Million
31,783 Added 1.78%
1,820,848 $106 Million
Q1 2020

May 14, 2020

BUY
$46.4 - $67.43 $5.41 Million - $7.86 Million
116,574 Added 6.97%
1,789,065 $98.8 Million
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $61 Million - $79.5 Million
1,238,753 Added 285.6%
1,672,491 $108 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $1.05 Million - $1.25 Million
-24,653 Reduced 5.38%
433,738 $22.1 Million
Q2 2019

Aug 01, 2019

SELL
$44.62 - $49.34 $1.13 Million - $1.25 Million
-25,329 Reduced 5.24%
458,391 $20.9 Million
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $387,445 - $461,980
-8,587 Reduced 1.74%
483,720 $29.7 Million
Q4 2018

Feb 12, 2019

BUY
$48.76 - $63.23 $418,702 - $542,956
8,587 Added 1.78%
492,307 $25.1 Million
Q3 2018

Nov 09, 2018

SELL
$55.19 - $62.25 $1.89 Million - $2.14 Million
-34,313 Reduced 6.62%
483,720 $0
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $43.8 Million - $54.5 Million
-865,910 Reduced 62.57%
518,033 $29 Million
Q1 2018

May 03, 2018

BUY
$59.92 - $68.98 $24.8 Million - $28.6 Million
414,591 Added 42.77%
1,383,943 $87.2 Million
Q3 2017

Nov 06, 2017

BUY
$55.23 - $63.74 $53.5 Million - $61.8 Million
969,352
969,352 $56.1 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.